Abbott Laboratories (NYSE:ABT)

The Established Pharmaceutical Products segment demonstrated a positive trajectory in both operating earnings and net sales between 2021 and 2025. Operating earnings increased from US$889 million to US$1,290 million over the five-year period, while net sales grew from US$4,718 million to US$5,536 million. This growth is reflected in the segment profit margin, which exhibited an overall upward trend, though with some fluctuation.

Segment Profit Margin Trend

The segment profit margin increased steadily from 18.84% in 2021 to 23.81% in 2023, indicating improving profitability relative to sales. A slight decrease to 23.74% occurred in 2024, followed by a further decline to 23.30% in 2025. Despite these recent decreases, the 2025 margin remains significantly higher than that of 2021.

The consistent growth in operating earnings and net sales suggests strong performance within this segment. The initial rise in segment profit margin indicates effective cost management or pricing strategies. The marginal decrease in the segment profit margin in the most recent two years warrants further investigation to determine the underlying causes, such as increased costs of goods sold, changes in product mix, or increased competition. However, the overall trend remains positive, suggesting continued strength in the Established Pharmaceutical Products segment.

Growth Rates

Between 2021 and 2025, operating earnings experienced a cumulative growth of approximately 45.0%. Net sales grew by roughly 17.4% over the same period. The segment profit margin increased by approximately 23.6% from 2021 to 2023, before experiencing a slight decline in the subsequent two years.

The segment’s ability to consistently increase both sales and earnings is a positive indicator. Monitoring the factors influencing the recent stabilization and slight decline in the segment profit margin will be crucial for maintaining and potentially improving future performance.

The Nutritional Products segment demonstrated a volatile performance over the five-year period. While net sales generally trended upwards, operating earnings and segment profit margin experienced significant fluctuations.

Operating Earnings

Operating earnings decreased substantially from 2021 to 2022, falling from US$1,763 million to US$706 million. A recovery was then observed in 2023, with earnings reaching US$1,333 million. This positive trend continued into 2024 and 2025, with earnings increasing to US$1,505 million and US$1,558 million respectively, though the rate of increase slowed.

Net Sales

Net sales experienced a slight decline between 2021 and 2022, decreasing from US$8,294 million to US$7,459 million. Subsequent years showed consistent growth, reaching US$8,154 million in 2023, US$8,413 million in 2024, and US$8,451 million in 2025. The growth rate appears to be moderating in the most recent periods.

Segment Profit Margin

The segment profit margin mirrored the volatility in operating earnings. It decreased significantly from 21.26% in 2021 to 9.47% in 2022. A substantial improvement occurred in 2023, with the margin rising to 16.35%. This upward trajectory continued through 2024 (17.89%) and 2025 (18.44%), indicating a strengthening of profitability within the segment. The margin in 2025, while improved, did not reach the levels observed in 2021.

The divergence between net sales and operating earnings, particularly in 2022, suggests potential pressures on cost of goods sold or operating expenses within the Nutritional Products segment. The subsequent recovery in both earnings and margin indicates successful mitigation of these pressures, although the slower growth in earnings relative to sales in the later years warrants further investigation.

The segment experienced a significant shift in financial performance between 2021 and 2025. Initially, the segment demonstrated strong profitability, but subsequent years reveal a consistent decline in both operating earnings and net sales, accompanied by a corresponding decrease in segment profit margin.

Operating Earnings Trend

Operating earnings peaked at US$6,667 million in 2022 before experiencing a substantial reduction. By 2025, operating earnings had fallen to US$1,740 million, representing a decrease of approximately 74% from the 2022 high. This indicates a considerable erosion of the segment’s earnings power.

Net Sales Trend

Net sales followed a similar trajectory to operating earnings. While sales increased from US$15,644 million in 2021 to US$16,584 million in 2022, they subsequently declined, reaching US$8,937 million in 2025. This represents a decrease of approximately 46% from the 2022 peak, suggesting weakening demand or increased competitive pressures.

Segment Profit Margin Analysis

The segment profit margin initially remained relatively stable, at approximately 40% in 2021 and 2022. However, beginning in 2023, the margin began a consistent downward trend. It decreased from 24.36% in 2023 to 19.47% in 2025. This decline suggests that the segment is becoming less efficient at converting sales into profits, potentially due to rising costs, pricing pressures, or a shift in product mix.

The combined effect of declining sales and decreasing profit margins resulted in a substantial reduction in operating earnings. The trend suggests increasing challenges within this segment, warranting further investigation into the underlying causes of the performance deterioration.

The Medical Devices segment demonstrated a consistent pattern of growth in both operating earnings and net sales between 2021 and 2025. Operating earnings increased from US$4,514 million to US$7,212 million over the five-year period, while net sales rose from US$14,367 million to US$21,387 million. This growth was accompanied by a generally improving segment profit margin.

Operating Earnings Trend

Operating earnings experienced a slight decrease between 2021 and 2022, falling from US$4,514 million to US$4,409 million. However, a strong upward trend followed, with earnings increasing each year from 2022 through 2025. The largest year-over-year increase occurred between 2023 and 2024, with an addition of US$847 million.

Net Sales Trend

Net sales exhibited a steady increase throughout the period. Growth was relatively consistent between 2021 and 2023, with a more substantial increase observed between 2023 and 2025. The increase in net sales from 2024 to 2025 was particularly notable, adding US$2,401 million.

Segment Profit Margin Analysis

The segment profit margin initially decreased from 31.42% in 2021 to 30.02% in 2022. It then returned to 31.42% in 2023 and continued to improve, reaching 32.41% in 2024 and 33.72% in 2025. This indicates increasing profitability relative to sales within the segment, suggesting improved operational efficiency or pricing power.

Overall, the Medical Devices segment demonstrated positive financial performance across all measured metrics. The combination of increasing operating earnings, growing net sales, and an expanding segment profit margin suggests a strengthening position and effective management within this segment.

The Established Pharmaceutical Products segment demonstrates a generally positive financial performance over the observed period. Operating earnings consistently increased from 2021 to 2024, before experiencing a slight increase in 2025. Total assets also exhibited an upward trajectory, with a more pronounced increase between 2024 and 2025. This asset growth, coupled with increasing operating earnings, has influenced the segment’s Return on Assets (ROA).

Operating Earnings Trend

Operating earnings increased from US$889 million in 2021 to US$1,290 million in 2025. The most significant growth occurred between 2021 and 2023, with increases of approximately 18% and 16% respectively. Growth slowed between 2023 and 2024, at approximately 2%, before resuming with a 5% increase in 2025.

Total Assets Trend

Total assets increased from US$2,789 million in 2021 to US$3,540 million in 2025. The increase was relatively steady from 2021 to 2024, with a more substantial increase of approximately 15% between 2024 and 2025. This suggests a potential acceleration in investment within the segment during the latter period.

Segment ROA Trend

Segment ROA increased from 31.88% in 2021 to a peak of 39.94% in 2024, indicating improving efficiency in asset utilization. While still strong, ROA decreased slightly to 36.44% in 2025. This decrease coincides with the larger increase in total assets observed in that year, suggesting that the growth in assets may not have immediately translated into proportional earnings growth. The ROA remained above 36% throughout the entire period, indicating consistently strong profitability relative to the assets employed.

Overall, the segment demonstrates a positive trend in both earnings and asset base. The slight decrease in ROA in 2025 warrants monitoring to determine if it represents a temporary fluctuation or the beginning of a more sustained trend.

The Nutritional Products segment demonstrated fluctuating performance between 2021 and 2025. Operating earnings experienced a significant decline in 2022 before recovering and exhibiting moderate growth through 2025. Total assets consistently increased over the five-year period, though at a varying rate. Segment Return on Assets (ROA) mirrored the earnings trend, initially decreasing sharply, then recovering, and stabilizing.

Operating Earnings

Operating earnings decreased substantially from US$1,763 million in 2021 to US$706 million in 2022, representing a decline of approximately 60%. A recovery began in 2023, with earnings reaching US$1,333 million, and continued through 2025, reaching US$1,558 million. The growth from 2023 to 2025 was more moderate than the initial recovery from 2022.

Total Assets

Total assets increased each year from 2021 to 2025. The increase from 2021 to 2022 was US$200 million. Growth accelerated from 2022 to 2023 (US$645 million) and continued at a similar pace from 2023 to 2024 (US$134 million), before slowing to US$387 million from 2024 to 2025. This suggests a potential deceleration in asset accumulation towards the end of the period.

Segment ROA

Segment ROA experienced a dramatic decrease from 51.47% in 2021 to 19.48% in 2022, coinciding with the decline in operating earnings. ROA improved to 31.22% in 2023 and further to 34.17% in 2024. However, it experienced a slight decrease in 2025, settling at 32.52%. While the ROA recovered from its low in 2022, it did not return to the levels observed in 2021, indicating that asset utilization efficiency, relative to earnings, remained lower despite the earnings recovery.

The segment’s asset base expanded while earnings fluctuated, resulting in a corresponding volatility in ROA. The consistent asset growth, coupled with the stabilization of ROA in the later years, suggests a potential focus on leveraging the increased asset base for future earnings growth.

The segment Return on Assets (ROA) for Diagnostic Products demonstrates a significant shift over the observed five-year period. Initially strong, performance declined substantially, indicating evolving profitability relative to asset utilization within this segment.

Operating Earnings Trend

Operating earnings peaked in 2022 at US$6,667 million, representing an increase from US$6,256 million in 2021. However, a marked decrease is evident in subsequent years, falling to US$2,433 million in 2023, US$2,073 million in 2024, and further to US$1,740 million in 2025. This represents a substantial contraction in earnings power.

Total Assets Trend

Total assets exhibited relative stability between 2021 and 2024, fluctuating between approximately US$7,678 million and US$7,985 million. A noticeable increase occurred in 2025, with total assets reaching US$8,273 million. This suggests continued investment in the segment despite declining profitability.

Segment ROA Analysis

Segment ROA began at a high of 81.26% in 2021, increasing to 83.49% in 2022, coinciding with the peak in operating earnings. A dramatic decline commenced in 2023, with ROA falling to 31.32%. This downward trend continued, reaching 27.00% in 2024 and 21.03% in 2025. The decrease in ROA is attributable to the significant reduction in operating earnings, coupled with relatively stable, and ultimately increasing, asset levels.

The consistent decline in Segment ROA, despite a late-period increase in total assets, suggests diminishing efficiency in generating profits from the assets employed within the Diagnostic Products segment. Further investigation into the drivers of the earnings decline is warranted.

The Medical Devices segment demonstrated a positive trajectory in financial performance between 2021 and 2025. Operating earnings and total assets both increased over this period, contributing to an improving return on assets.

Operating Earnings

Operating earnings for the Medical Devices segment experienced moderate fluctuations. A slight decrease was observed from 2021 to 2022, followed by consistent growth through 2025. Earnings increased from US$4,514 million in 2021 to US$7,212 million in 2025, representing a cumulative increase of approximately 59.8%. The most substantial year-over-year increase occurred between 2022 and 2023.

Total Assets

Total assets allocated to the Medical Devices segment exhibited a steady upward trend throughout the analyzed period. Beginning at US$7,261 million in 2021, assets grew to US$10,689 million by 2025, indicating a roughly 47.2% increase in asset base. Growth was consistent year-over-year, suggesting ongoing investment within the segment.

Segment ROA

The segment’s Return on Assets (ROA) showed overall improvement. While a decrease was noted from 62.17% in 2021 to 56.21% in 2022, ROA subsequently increased each year, reaching 67.47% in 2025. This indicates increasing efficiency in utilizing assets to generate earnings within the Medical Devices segment. The increase in ROA from 2022 to 2025 suggests that the growth in operating earnings outpaced the growth in total assets, enhancing profitability.

In summary, the Medical Devices segment experienced growth in both earnings and asset base, resulting in a strengthening ROA. The segment’s performance appears to be on a positive trend, with increasing efficiency in asset utilization.

The Established Pharmaceutical Products segment experienced consistent growth in net sales from 2021 to 2025, increasing from US$4,718 million to US$5,536 million. Total assets within the segment also generally increased over the period, though with some fluctuation, rising from US$2,789 million in 2021 to US$3,540 million in 2025. However, the segment asset turnover ratio exhibited a more complex pattern.

Segment Asset Turnover Trend

The segment asset turnover ratio, which measures the efficiency with which assets are used to generate sales, remained relatively stable between 2021 and 2024, fluctuating between 1.62 and 1.70. A slight increase was observed from 1.69 in 2021 to 1.70 in 2022, followed by a decrease to 1.62 in 2023, and a recovery to 1.68 in 2024. However, 2025 saw a noticeable decline to 1.56.

The increase in net sales did not translate into a proportional increase in asset turnover throughout the entire period. While sales grew by approximately 17.3% from 2021 to 2025, the asset turnover ratio decreased by approximately 7.7% over the same timeframe. This suggests a potential decrease in the efficiency of asset utilization within the Established Pharmaceutical Products segment in the most recent year. The increase in total assets in 2025, coupled with a slower growth rate in net sales compared to prior years, likely contributed to this decline.

Asset Growth vs. Turnover

The largest increase in total assets occurred between 2024 and 2025 (US$453 million), while the corresponding increase in net sales was comparatively smaller (US$342 million). This disparity indicates that the segment invested more heavily in assets during 2025 without achieving a commensurate increase in sales, resulting in the reduced asset turnover ratio.

Further investigation would be required to determine the specific reasons for the decline in asset turnover in 2025. Potential factors could include investments in new, yet-to-be-productive assets, changes in inventory management practices, or a shift in the sales mix towards lower-margin products.

The Nutritional Products segment experienced fluctuating net sales between 2021 and 2025. Sales decreased from US$8,294 million in 2021 to US$7,459 million in 2022, before recovering to US$8,154 million in 2023. Further growth was observed in 2024 and 2025, reaching US$8,413 million and US$8,451 million respectively. Total assets within the segment generally increased over the five-year period, moving from US$3,425 million in 2021 to US$4,791 million in 2025.

Segment Asset Turnover

The segment asset turnover ratio exhibited a consistent downward trend from 2021 to 2025. Beginning at 2.42 in 2021, the ratio declined to 2.06 in 2022, and continued to decrease to 1.91 in 2023. The ratio remained stable at 1.91 in 2024, before falling to 1.76 in 2025. This indicates a decreasing efficiency in utilizing assets to generate sales within the Nutritional Products segment.

Despite increases in net sales in the later years of the period, the declining asset turnover suggests that asset growth outpaced sales growth. This could be due to investments in new assets that have not yet fully contributed to revenue generation, or potentially indicate inefficiencies in asset management. The consistent decline warrants further investigation to understand the underlying drivers and potential implications for profitability.

The Diagnostic Products segment experienced a decline in net sales from 2021 through 2025. Simultaneously, total assets remained relatively stable before increasing in the final year. Consequently, the segment asset turnover ratio exhibited a consistent downward trend over the five-year period.

Net Sales Trend

Net sales decreased from US$15,644 million in 2021 to US$8,937 million in 2025. The most significant decline occurred between 2021 and 2023, with a more moderate decrease observed in the subsequent two years. This represents a roughly 43% reduction in sales over the period.

Total Assets Trend

Total assets for the Diagnostic Products segment were relatively consistent from 2021 to 2023, fluctuating between US$7,699 million and US$7,985 million. A noticeable increase to US$8,273 million was observed in 2025. This suggests a potential investment in assets despite declining sales.

Segment Asset Turnover

The segment asset turnover ratio decreased from 2.03 in 2021 to 1.08 in 2025. This indicates a diminishing efficiency in utilizing assets to generate sales. The ratio’s decline mirrors the decrease in net sales, while the relatively stable, and then increasing, asset base exacerbates the downward trend. A ratio of 1.08 suggests that for every dollar of assets, the segment generates approximately US$1.08 in sales.

The combination of decreasing sales and relatively stable, then increasing, asset levels resulted in a substantial reduction in the segment asset turnover ratio. This trend warrants further investigation to understand the underlying causes of the sales decline and the rationale behind the asset level changes.

The Medical Devices segment experienced growth in both net sales and total assets between 2021 and 2025. While both metrics increased over the period, the segment asset turnover exhibited a more nuanced pattern.

Net Sales

Net sales for the Medical Devices segment demonstrated a consistent upward trend, increasing from US$14,367 million in 2021 to US$21,387 million in 2025. This represents a cumulative growth of approximately 48.7% over the five-year period.

Total Assets

Total assets allocated to the Medical Devices segment also increased steadily, rising from US$7,261 million in 2021 to US$10,689 million in 2025. This indicates a 47.2% increase in asset investment within the segment during the analyzed timeframe.

Segment Asset Turnover

The segment asset turnover ratio initially decreased from 1.98 in 2021 to 1.87 in 2022, suggesting a slight decrease in the efficiency of asset utilization in generating sales. The ratio remained at 1.87 in 2023. However, the ratio then increased to 2.00 in both 2024 and 2025, indicating improved asset utilization efficiency in those years. The 2024 and 2025 levels represent a return to, and slight exceedance of, the 2021 ratio.

The concurrent increases in both net sales and total assets, coupled with the initial decline and subsequent recovery in asset turnover, suggest that the segment effectively managed its asset base to support sales growth, particularly in the later years of the period. The stabilization and improvement in asset turnover from 2023 to 2025 is a positive indicator of operational efficiency.

Analysis of capital expenditures relative to depreciation within the Established Pharmaceutical Products segment reveals a generally stable investment pattern over the five-year period. Additions to property and equipment have fluctuated modestly, while depreciation has exhibited a consistent upward trajectory, influencing the segment capital expenditures to depreciation ratio.

Additions to Property and Equipment

Additions to property and equipment increased from US$169 million in 2021 to US$175 million in 2022, then continued to US$185 million in 2023. A slight decrease to US$183 million was noted in 2024, followed by a further reduction to US$169 million in 2025, returning to the level observed in 2021. This suggests a cyclical pattern of investment, potentially linked to specific project timelines or strategic initiatives.

Depreciation

Depreciation expense demonstrated a consistent increase throughout the period, rising from US$94 million in 2021 to US$104 million in 2023. A minor decrease to US$96 million occurred in 2024, before increasing again to US$101 million in 2025. This steady increase likely reflects the ongoing amortization of prior capital investments.

Segment Capital Expenditures to Depreciation Ratio

The segment capital expenditures to depreciation ratio remained relatively stable between 2021 and 2023, holding at 1.80 in 2021 and 2022, and decreasing slightly to 1.78 in 2023. An increase to 1.91 was observed in 2024, indicating a greater level of capital investment relative to depreciation. The ratio then decreased to 1.67 in 2025, coinciding with the reduction in additions to property and equipment. A ratio consistently above 1.0 suggests that investment in capital assets exceeds the annual depreciation expense, indicating ongoing renewal and expansion of the asset base.

Overall, the segment appears to be maintaining its asset base with consistent investment, although the level of investment relative to depreciation experienced some fluctuation. The decrease in the capital expenditures to depreciation ratio in 2025 warrants further investigation to determine if it signals a shift in investment strategy or a change in the asset lifecycle within this segment.

The Nutritional Products segment experienced fluctuating capital expenditures relative to depreciation over the five-year period. Additions to property and equipment and depreciation both exhibited generally increasing values, but at different rates, resulting in a dynamic segment capital expenditures to depreciation ratio.

Segment Capital Expenditures to Depreciation

The ratio began at 1.15 in 2021, indicating that capital expenditures exceeded depreciation expense by 15%. This ratio increased substantially to 1.62 in 2022, suggesting a greater investment in capital assets compared to the depreciation of existing assets. A significant rise was then observed in 2023, with the ratio reaching 2.95, implying a considerably larger investment in property and equipment relative to depreciation.

In 2024, the ratio decreased to 2.40, indicating a moderation in the pace of capital expenditure growth compared to depreciation. The ratio continued to decline in 2025, falling to 1.73. This suggests a return towards a level more similar to that observed in 2022, though still higher than the initial value in 2021.

Additions to property and equipment peaked in 2023 at US$457 million, a substantial increase from US$174 million in 2021. While remaining significant, these additions decreased to US$382 million in 2024 and further to US$302 million in 2025. Depreciation expense demonstrated a more consistent, albeit gradual, increase throughout the period, moving from US$151 million in 2021 to US$175 million in 2025.

The observed pattern suggests periods of substantial investment in the Nutritional Products segment, particularly in 2023, followed by a moderation in capital spending. The decreasing ratio in the latter years indicates that depreciation expense is beginning to catch up with the accumulated capital investments.

Analysis of segment capital expenditures to depreciation for Diagnostic Products reveals a fluctuating relationship between investment in property, plant, and equipment and the associated depreciation expense over the five-year period. Additions to property and equipment decreased from 2021 to 2023, before stabilizing and experiencing a slight increase in 2024 and 2025. Depreciation expense exhibited a more pronounced decrease from 2021 to 2022, followed by relative stability and a gradual increase through 2025.

Additions to Property and Equipment

Additions to property and equipment began at US$980 million in 2021, declining to US$832 million in 2022, and further to US$750 million in 2023. A modest recovery was observed in 2024, reaching US$758 million, with a further slight increase to US$761 million in 2025. This suggests a period of reduced investment followed by stabilization.

Depreciation Expense

Depreciation expense decreased significantly from US$760 million in 2021 to US$494 million in 2022. It remained relatively stable at US$499 million in 2023, before increasing to US$521 million in 2024 and US$533 million in 2025. The initial decline likely reflects the depreciation of previously invested assets, while the subsequent increases align with the recent additions to property and equipment.

Segment Capital Expenditures to Depreciation Ratio

The segment capital expenditures to depreciation ratio started at 1.29 in 2021. It increased substantially to 1.68 in 2022, reflecting the larger decrease in depreciation relative to capital expenditures. The ratio then decreased to 1.50 in 2023 and continued to decline, albeit at a slower pace, to 1.45 in 2024 and 1.43 in 2025. This indicates that, while investment continues, the rate of investment relative to depreciation is decreasing, suggesting a potential shift in capital allocation strategy or a catch-up in depreciation expense.

Overall, the trend suggests a period of decreasing investment in property and equipment followed by stabilization, coupled with a significant initial decline in depreciation expense and a subsequent gradual increase. The capital expenditures to depreciation ratio indicates a diminishing rate of investment relative to depreciation over the observed period.

Analysis of capital expenditures relative to depreciation within the Medical Devices segment reveals a fluctuating pattern over the five-year period. Additions to property and equipment demonstrate an increasing trend from 2021 through 2025, while depreciation also generally increases, though at a slower pace. The resulting ratio of segment capital expenditures to depreciation exhibits corresponding variability.

Segment Capital Expenditures to Depreciation

The ratio began at 1.22 in 2021, indicating that capital expenditures exceeded depreciation expense by 22%. This suggests investment in the segment’s asset base was outpacing the recorded decline in asset value.

In 2022, the ratio decreased to 1.08, signifying a narrowing gap between capital expenditures and depreciation. This implies a moderation in investment relative to asset value decline.

A substantial increase is observed in 2023, with the ratio reaching 1.92. This represents a significant rise in capital expenditures compared to depreciation, potentially indicating a period of substantial investment in new assets or expansion within the Medical Devices segment.

The ratio decreased slightly to 1.84 in 2024, and further to 1.74 in 2025. While still considerably higher than the 2021 and 2022 levels, these values suggest a stabilization of the investment pace relative to depreciation. The continued level above 1.7 indicates ongoing investment in the segment’s asset base.

The trend in additions to property and equipment supports the observed changes in the ratio. The increase in capital expenditures from 2022 to 2023 directly contributed to the rise in the ratio, while the continued, though moderated, increases in subsequent years maintain a level significantly above the earlier period. Depreciation expense increases are present, but do not fully offset the growth in capital expenditures, resulting in the observed ratio behavior.

Overall, the Medical Devices segment appears to have undergone a period of increased investment starting in 2023, as evidenced by the elevated capital expenditures to depreciation ratio. While the rate of increase has moderated in the most recent periods, investment continues to exceed depreciation, suggesting ongoing asset base expansion or renewal.